Saturday 17 October 2026
Export SYK’s income statement to Excel — free account
Stryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
294.66
1.43
+0.49%
Follow SYK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
47.95 | 41.40 | 37.64 | 32.36 |
P/S ratio |
5.80 | 5.35 | 4.98 | 4.67 | |
P/FCF ratio |
33.36 | 31.36 | 27.53 | 25.68 | |
P/Operating CF |
91.79 | 62.68 | 216.55 | 95.75 | |
P/B ratio |
6.49 | 5.99 | 5.48 | 5.03 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.34 | 5.82 | 5.44 | 5.12 | |
EV/EBITDA |
32.16 | 24.02 | 22.16 | 19.57 | |
EV/Operating CF |
32.00 | 28.96 | 25.60 | 23.93 | |
EV/FCF |
36.48 | 34.11 | 30.10 | 28.12 | |
Quick Ratio |
0.94 | 1.04 | 1.04 | 1.08 | |
Current Ratio |
1.85 | 1.89 | 2.11 | 2.16 | |
Net Debt/EBITDA |
9.18 | 5.55 | 9.51 | 5.87 | |
Debt/Assets |
35.27% | 33.15% | 31.81% | 31.17% | |
Debt/Equity |
0.76 | 0.71 | 0.64 | 0.62 | |
Asset Turnover |
0.54 | 0.55 | 0.55 | 0.55 | |
Operating CF/Net income |
1.79 | 2.52 | 0.78 | 0.99 | |
Capex/Depreciation |
(0.07) | (1.37) | (0.55) | (0.68) | |
Interest Coverage |
— | 5.80 | 6.32 | 11.77 | |
Research and Development Expense of Revenue |
6.77% | 5.59% | 6.86% | 6.59% | |
Selling, General and Administrative Expense of Revenue |
33.76% | 31.06% | 37.89% | 33.83% | |
Intangible Assets out of Total Assets |
0.53 | 0.52 | 0.53 | 0.53 | |
Share Based Compensation of Revenue |
1.02% | 0.67% | 1.45% | 0.82% | |
Graham Net Nets |
(0.08) | (0.08) | (0.08) | (0.08) | |
Graham Number |
99.41 | 105.86 | 108.57 | 117.02 | |
Earnings Yield |
2.09% | 2.42% | 2.66% | 3.09% | |
Free Cash Flow Yield |
3.00% | 3.19% | 3.63% | 3.89% | |
Revenue per Share |
15.84 | 18.76 | 15.72 | 17.18 | |
Operating CF per Share |
4.03 | 5.61 | 1.52 | 3.29 | |
Capex per Share |
(0.06) | (1.13) | (0.43) | (0.53) | |
Free Cash Flow per Share |
3.97 | 4.47 | 1.08 | 2.76 | |
Cash per Share |
8.74 | 10.73 | 7.74 | 9.06 | |
Shareholders Equity per Share |
56.97 | 58.66 | 60.01 | 62.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
56.97 | 58.66 | 60.01 | 62.55 | |
Free Cash Flow |
1,518.00 | 1,710.00 | 415.00 | 1,059.00 | |
Working Capital |
6,297.00 | 6,961.00 | 7,023.00 | 7,734.00 | |
Capital Expenditures |
(22.00) | (433.00) | (166.00) | (202.00) | |
Net Current Asset Value |
(11,561.00) | (10,669.00) | (9,974.00) | (9,524.00) | |
EV/EBIT |
42.18 | 29.88 | 27.58 | 23.89 | |
Capex to Sales |
0.00 | 0.06 | 0.03 | 0.03 | |
Price to Operating Income |
38.56 | 27.48 | 25.22 | 21.82 | |
| Other line items | |||||
Average Receivables |
3,689.50 | 4,013.00 | 3,766.00 | 3,830.50 | |
Average Payables |
1,417.50 | 1,739.00 | 1,528.00 | 1,552.50 | |
Average Inventory |
5,331.00 | 5,042.00 | 5,262.00 | 5,405.00 | |
Average Assets |
45,445.00 | 45,407.50 | 46,148.50 | 47,130.50 | |
Average Common Equity |
20,967.00 | 21,527.00 | 21,954.50 | 22,589.50 |
Columns are period end dates